Table 1.
Characteristics of the patients with COVID-19 in ICU (n = 51).
| Characteristics | Number (%) | |
|---|---|---|
| Age | ||
| ≤65 years | 32 (62.75) | |
| >65 years | 19 (37.25) | |
| Sex | ||
| Male | 35 (68.63) | |
| Female | 16 (31.37) | |
| BMI>25 (kg/m2) | 16 (31.37) | |
| Underlying medical conditions | ||
| Hypertension | 22 (43.14) | |
| DM | 7 (13.73) | |
| CHD | 12 (23.53) | |
| COPD | 2 (3.92) | |
| Cerebrovascular disease | 5 (9.80) | |
| Hepatopathy | 1 (1.96) | |
| Hemorrhage of digestive tract | 2 (3.92) | |
| Chronic kidney disease | 1 (1.96) | |
| Renal transplant | 1 (1.96) | |
| Malignant tumor | 0 | |
| Liver impairment | Value (mean ± SD) U/L | |
| On admission | 21 (41.18) | 53.13 ± 65.55 |
| ULN <ALT ≤20-fold ULN | 21 (41.18) | 53.13 ± 65.55 |
| ALT >20-fold ULN | 0 | |
| Hospitalization* | 39 (76.47)* | 70.54 ± 142.90 |
| ULN <ALT ≤20-fold ULN | 36 (70.59) | 118.23 ± 90.75 |
| ALT >20-fold ULN | 3 (5.88) | 1406.33 ± 262.58# |
| Treatment | ||
| Antibiotic therapy | 16 (31.37) | |
| Antiviral therapy | 38 (74.51) | |
| A combination of antibiotic and antiviral therapy | 11 (21.56) | |
| Multiple antiviral therapies (≥2) | 12 (23.53) | |
| Glucocorticoid therapy | 42 (82.35) | |
| Mechanical ventilation | 37 (72.55) | |
| ECMO | 3 (5.88) | |
*
Liver impairment ratio (hospitalization vs. on admission, P < 0.001).
#
Peak ALT level during hospitalization (HH patients vs. non-HH patients with liver impairment, P < 0.001).
ALT, alanine aminotransferase; BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ULN, upper limit of normal; ECMO: extracorporeal membrane oxygenation; SD, standard deviation; HH, hypoxic hepatitis.